Introduction
============

Patient-Controlled Analgesia (PCA) via the epidural route provides an excellent means of decreasing pain after orthopedic, gynecologic, or abdominal surgery \[[@B1]\]. However, some adverse effects have been reported, especially postoperative nausea and vomiting (PONV). The physical and psychological complications of PONV include; aspiration of vomitus, esophageal trauma (Mallory-Weiss syndrome), dehydration, alkalemia, and emotional depression. Patients are encouraged to begin physical therapy on the day after surgery, but persistent PONV may interfere with physical therapy activities, and this prolongs hospitalization and increases medical costs. A number of therapies are available for the management of PONV, but no therapy is entirely efficient \[[@B2],[@B3]\].

Transdermal scopolamine (TDS) patches are highly effective for managing motion sickness, and were approved in 1997 by the Food and Drug Administration for the prevention of nausea and vomiting after anesthesia. Scopolamine is an anticholinergic agent that acts on the central nervous system by blocking cholinergic transmission from vestibular nuclei to higher CNS centers and from the reticular formation to the vomiting center \[[@B4]\]. Patches contain 1.5 mg of scopolamine and deliver the agent at 5 µg/hr for 72 hours. It has been reported that TDS patches decrease the nausea and vomiting induced by intrathecal or epidural morphine after cesarean delivery \[[@B5],[@B6]\] and other types of surgery \[[@B7],[@B8]\]. Furthermore, the prophylactic use of a TDS patch plus ondansetron has been described for the prevention of PONV, and has been found to be superior to ondansetron alone \[[@B9],[@B10]\]. However, the combined use of a TDS patch and dexamethasone (a popularly used antiemetic) has not been properly explored, and thus, we compared the effects of a TDS patch plus IV dexamethasone with those of other antiemetics, namely, IV dexamethasone alone and IV dexamethasone plus IV ramosetron, on the prevention of PONV in patients that received epidural PCA after major orthopedic surgery.

Materials and Methods
=====================

Patients that underwent elective, primary, or revisionary total knee or hip replacement surgery or anterior cruciate ligament reconstruction under spinal anesthesia and postoperative epidural PCA were eligible for participation in this study. The study protocol and informed consent forms used were in accordance with the ethical standards issued by our institutional Human Investigation Committee. All patients were of ASA I-III and aged 20-75, and all provided consent on the day before surgery. Patients with the following conditions were excluded; a history of drug-abuse, infection at the lumbar spine, coagulation disorder, uncontrolled diabetes, glaucoma, pregnancy, breast-feeding, a history of dementia, and current steroid use. Patients were allocated to 3 treatment groups using a random numbers table: Group D (n = 40) received dexamethasone 8 mg intravenously (Dae Won, Korea); Group DR (n = 40) received dexamethasone 8 mg and ramosetron 0.3 mg intravenously (Nasea®, Astellas, Seoul); and Group DS (n = 40) received dexamethasone 8 mg and TDS (Kimite, Myung Moon, Korea).

Members of the three groups were similar in terms of age, weight, height, and duration of surgery ([Table 1](#T1){ref-type="table"}). All patients completed a VAS score for nausea and did not complain of a significant opioid or drug-related adverse effect during the first 24 hours after surgery.

On the day of surgery, patients in the DS group attached a scopolamine patch behind one ear (on the preanesthetic area) at 30 min before anesthesia. All patients received spinalepidural combined anesthesia (Portex®, Smiths Medical, UK) plus 0.5% hyperbaric bupivacaine (Bupivacaine heavy, Hana Pharm, Korea) 10-12 mg. A 20 gauge epidural catheter was inserted to the L3/4 or L4/5 lumbar spinal level. Combined spinal-epidural anesthesia was sufficient for surgery, and all patients received dexamethasone 8 mg intravenously after confirming level of spinal anesthesia. In addition, members of the DR group were administered ramosetron 0.3 mg intravenously at the end of surgery. Hypotension during surgery (defined as a systolic blood pressure of \< 100 mmHg or \> 20% below the prespinal baseline) was treated with boluses of ephedrine 8 mg at the discretion of the attending anesthesiologist. Epidural PCA was started using a PCA pump (Accufuser®, Woo Young medical, Korea) at the end of surgery. The pump contained a 150 ml visible bag with hydromorphone 4 µg/ml (Dilid, Hana Pharm, Korea) and ropivacaine 1 mg/ml (Naropin®, AstraZeneca, Australia). Pump delivery rates were set at 5 ml/hr and bolus doses at 0.5 ml with a lockout time of 15 min for 24 hours. Ondansetron 4 mg was administered intravenously as a rescue therapy in the postanesthesia care unit and ward for nausea and vomiting.

Measurements were taken at 0-6, 6-12, and 12-24 h postoperatively. Anesthesiologists (unaware of patient group allocations) recorded the severity of nausea, the presence of vomiting, and the receipt of rescue antiemetics. Severity of nausea was rated using a VAS scale (0 = no symptoms and 100 = worst imaginable symptoms) during each time period. The presence of vomiting and side effects (dry mouth, blurred vision, drowsiness), and the use of rescue antiemetics were also recorded. A pilot study on the incidence of vomiting during the first 24 hours after surgery was performed using 10 patients of each group and 40% of group D, 20% of group DR, and 10% of Group DS were affected. The PASS 2008® program (Utah, USA) was used to determine sample sizes, and this analysis showed 34 patients per group were required to achieve 80% power to detect a linear trend at a significance level 0.05. Statistical analyses were performed using SPSS 14.0 for Windows (Chicago, IL). The One-way ANOVA test with Bonferroni correction was used to analyze parametric data. Categorical data were analyzed using the χ^2^ test or Fisher\'s exact test. Statistical significance was accepted for P values of \< 0.05.

Results
=======

All 120 patients completed a VAS form for nausea, PONV, rescue antiemetics, and adverse effects at each study period. Complete response rates (no nausea, no vomiting) over 24 hours were 47.5%, 50.0%, and 82.5% in groups D, DR, and DS, respectively. The proportions of patients that experienced nausea or vomiting over 24 hours were 55.0 and 50.0%, 17.5% and 50.0%, and 25.0% and 10.0%, respectively, and the overall proportions of patients who required rescue antiemetics during the same postoperative period were 35.0%, 22.5%, and 5.0% in groups D, DR, DS, respectively ([Table 2](#T2){ref-type="table"}).

Patients in group DS had significant lower nausea VAS scores at 6-12 and 12-24 hours than patients in group D (P = 0.004) and at 0-6 hours than patients in group DR (P = 0.009). The incidence of vomiting was significantly lower at 6-12 and 12-24 hours in group DS than in group D (P = 0.037, 0.029), and at 0-6 hours than in group DR (P = 0.029). The proportion of patients who required rescue antiemetics was significantly lower in group DS than in group D at 12-24 hours (P = 0.026), and than in group DR at 0-6 hours (P = 0.026) ([Table 2](#T2){ref-type="table"}). None of the 120 patients complained of blurred vision, and no significant inter-group difference was observed for dry mouth or drowsiness ([Table 3](#T3){ref-type="table"}). Other adverse effects, such as, agitation, hallucination, and amnesia, were not observed.

Discussion
==========

Recently, dexamethasone and 5-HT3 receptor antagonists have been used to prevent chemotherapy-induced nausea/vomiting and PONV. This is because corticosteroids may reduce 5-HT3 levels in neural tissues by depleting its precursor tryptophan \[[@B11]\], and because their anti-inflammatory effects may prevent serotonin release in the gut \[[@B12]\]. Furthermore, a combination of dexamethasone and 5-HT3 receptor antagonist has been reported to be effective and safe for preventing PONV \[[@B13],[@B14]\]. However, in the present study, the overall rate of PONV in groups D and DR were 55% and 50%, respectively. Szarvas et al. \[[@B15]\] reported that in patients that have undergone major orthopedic surgery with intrathecal morphine for postoperative pain and prophylactic IV dexamethasone or IV dexamethasone plus ondansetron, the incidences of PONV during the 0-24 hour immediate postoperative period were 67% and 40%, respectively, which concurs with our results. Furthermore, they concluded that dexamethasone monotherapy lacks efficacy. In addition, they suggested that dexamethasone better controls delayed PONV due to its relatively long biological half-life (36-72 hours). Thus, the 24-hour observation period used in the present study may not have been sufficient to identify the beneficial effects of dexamethasone. Ramosetron has a more potent, longer acting effect against PONV than granisetron \[[@B16]\]. Therefore, we presume that over the longer term, the prophylactic use of dexamethasone plus ramosetron may have a better effect on PONV comparing this study.

Scopolamine is a nonpolar, tertiary amino compound, and a muscarinic acetylcholine antagonist. Its pharmacodynamic characteristics include good absorption in the GI tract and excellent blood-brain barrier penetration. Furthermore, it has peripheral antimuscarinic properties and central sedative, antiemetic, and amnesic effects. When given orally or parenterally, scopolamine has a relative short half-life and many induce considerable dose-dependent adverse effects (such as, vertigo, a dry mouth, drowsiness, a visual disturbance, hallucinations, agitation). Because scopolamine has a narrow therapeutic range, a transdermal form has been developed to minimize the relatively high incidence of side effects associated with orally or parenterally scopolamine. The commercially available TDS patch (4 layers, thickness 0.2 mm, size 2.5 cm^2^) contains a drug reservoir of 1.5 mg and delivers a priming dose of 140 µg to achieve a steady state plasma concentration of 56-245 pg/ml. The patch releases 0.5 mg of scopolamine over 3 days (a release rate 5 µg) \[[@B4]\].

Although scopolamine is effective at preventing PONV, concerns have been raised regarding its use because of its undesirable side effects and its relatively slow onset of action. In a systemic review of the efficacy and safety of TDS for the prevention of PONV, Kranke et al. \[[@B17]\] suggested a 17% reduction in PONV at the expense of a 29% increase in side effects (visual disturbances and a dry mouth were found to be the most common). Furthermore, they found that the timing of TDS application, that is, the night before surgery, before induction, or during surgery, had no significant bearing on results. However, unlike earlier TDS studies \[[@B5]-[@B8]\], recent studies have found no different between prophylactic TDS and other antiemetic regimens with respect to the incidences of side effects. Gan et al. \[[@B9]\] compared an ondansetron group and an ondansetron plus TDS group, and found that the ondansetron plus TDS group showed less PONV and cumulative adverse effects over 48 hours. Sah et al. \[[@B10]\] also concluded that TDS better prevented PONV than a placebo after ambulatory cosmetic surgery with minimal adverse effects. White et al. \[[@B18]\] examined the use of TDS after major laparoscopic surgery, and found no difference between a dexamethasone plus TDS group and a dexamethasone plus ondansetron group with respect to PONV and side effects (except late dry mouth). They concluded that TDS is a cost-effective alternative to ondansetron. In the present study, the prevalences of the expected side effects of scopolamine (a dry mouth, blurred vision, and drowsiness) in the DS group were not significantly greater than the D and DR groups. No visual disturbance was complained of by any of the 120 study subjects. Furthermore, drowsiness was tolerable, and no patient required specific therapy or TDS discontinuation due to an adverse effect. The present study was confined to patients than underwent orthopedic surgery under spinal anesthesia with epidural PCA, and therefore, they were not administered a cholinesterase inhibitor to reverse the muscle paralysis that might inhibit the action of scopolamine. Some studies have reported that TDS is highly effective at preventing PONV in patients on PCA \[[@B19],[@B20]\], and thus, further studies on the prophylactic use of TDS for PONV are required for other types of surgery.

The present study has some limitations that should be considered. First, we did not include a control group (patients without prophylaxis), because we considered this unethical. Second, our PCA strategies were designed for the first 24 hours after surgery, and thus, further studies for are required to investigate the effects of the prolonged application and its adverse effects. Third, patients were not asked to submit a satisfaction score at the end of the study period. Fourth, all patients had an indwelling urinary catheter, and thus, we could not evaluate the effect of TDS on urinary retention.

Summarizing, the prophylactic use of a transdermal scopolamine patch plus IV dexamethasone was found to be more effective at preventing PONV than dexamethasone alone or dexamethasone plus ramosetron in patients that had undergone major orthopedic surgery on epidural PCA, and was found to have minimal side effects.
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Demographic Data
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Values are numbers or means ± SDs, n: number of patients. No significant inter-group differences were observed. Group D: the dexamethasone group, Group DR: the dexamethasone plus ramosetron group, and Group DS: the scopolamine plus dexamethasone group.
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Postoperative Nausea, Vomiting, Rescue Antiemetics, and Complete Response Rates and VAS Nausea Scores

![](kjae-58-50-i002)

Values are numbers and percentages (%). Group D: the dexamethasone group, Group DR: the dexamethasone plus ramosetron group, and Group DS: the scopolamine plus dexamethasone group. ^\*^P \< 0.05 in group D vs group DS, ^†^P \< 0.05 in group DR vs group DS.
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Adverse Effects in the Three Treatment Groups
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Values are numbers and percentages (%). No significant differences were observed between the three groups. Group D: the dexamethasone group, Group DR: the dexame-thasone plus ramosetron group, and Group DS: the scopolamine plus dexamethasone group.
